A Cost-Effectiveness Analysis of Abatacept, Tocilizumab, And Tnf-Inhibitor Compared With Rituximab As A Second-Line Therapy For Treatment of Rheumatoid Arthritis
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1110
https://www.valueinhealthjournal.com/article/S1098-3015(16)32476-7/fulltext
Title :
A Cost-Effectiveness Analysis of Abatacept, Tocilizumab, And Tnf-Inhibitor Compared With Rituximab As A Second-Line Therapy For Treatment of Rheumatoid Arthritis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32476-7&doi=10.1016/j.jval.2016.09.1110
First page :
A538
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1044